Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer

Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer

Docetaxel (DTX) was the first chemotherapeutic agent to demonstrate significant efficacy in the treatment of men with metastatic castration-resistant prostate cancer. However, response to DTX is generally short-lived, and relapse eventually occurs due to emergence of drug-resistance. We previously e...

Full description

Bibliographic Details
Main Authors: Thiago S. Lima, Luciano O. Souza, Diego Iglesias-Gato, Johanna Elversang, Flemming Steen Jørgensen, Tuula Kallunki, Martin A. Røder, Klaus Brasso, José M.A. Moreira
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
metastatic castration-resistant prostate cancer
docetaxel resistance
cellular models
androgen independence
drug repurposing
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.869461/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.869461/full

Similar Items